Akari Therapeutics (AKTX) Non Operating Investment Income (2026)

Akari Therapeutics' (AKTX) quarterly Non Operating Investment Income came in at $230000.0 in Q1 2026.

Akari Therapeutics (AKTX) Non Operating Investment Income (2026) Analysis & Trends

Akari Therapeutics has disclosed Non Operating Investment Income across 1 years of filings, most recently posting $230000.0 for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - 235,807.00
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - 230,000.00
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn -
9 Abivax 90.15 Bn 90.15 Bn - -
10 Regeneron Pharmaceuticals 63.59 Bn 54.83 Bn 3.31 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 230,000.00
Mar 31, 2026 230,000.00